全文获取类型
收费全文 | 3358篇 |
免费 | 201篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 99篇 |
妇产科学 | 88篇 |
基础医学 | 491篇 |
口腔科学 | 121篇 |
临床医学 | 245篇 |
内科学 | 856篇 |
皮肤病学 | 167篇 |
神经病学 | 282篇 |
特种医学 | 109篇 |
外科学 | 293篇 |
综合类 | 7篇 |
一般理论 | 2篇 |
预防医学 | 181篇 |
眼科学 | 18篇 |
药学 | 264篇 |
中国医学 | 11篇 |
肿瘤学 | 335篇 |
出版年
2024年 | 4篇 |
2023年 | 42篇 |
2022年 | 77篇 |
2021年 | 142篇 |
2020年 | 86篇 |
2019年 | 134篇 |
2018年 | 112篇 |
2017年 | 97篇 |
2016年 | 93篇 |
2015年 | 124篇 |
2014年 | 160篇 |
2013年 | 167篇 |
2012年 | 254篇 |
2011年 | 288篇 |
2010年 | 138篇 |
2009年 | 148篇 |
2008年 | 241篇 |
2007年 | 200篇 |
2006年 | 179篇 |
2005年 | 193篇 |
2004年 | 168篇 |
2003年 | 137篇 |
2002年 | 106篇 |
2001年 | 28篇 |
2000年 | 23篇 |
1999年 | 22篇 |
1998年 | 17篇 |
1997年 | 17篇 |
1996年 | 17篇 |
1995年 | 10篇 |
1994年 | 15篇 |
1993年 | 15篇 |
1992年 | 9篇 |
1991年 | 20篇 |
1990年 | 17篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1987年 | 12篇 |
1986年 | 8篇 |
1985年 | 10篇 |
1984年 | 7篇 |
1983年 | 9篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1976年 | 3篇 |
1943年 | 2篇 |
1930年 | 2篇 |
1896年 | 1篇 |
排序方式: 共有3592条查询结果,搜索用时 15 毫秒
71.
72.
Muhammad Ahsan Javed Georg Beyer Nha Le Alessio Vinci Helen Wong Daniel Palmer Robert D. Morgan Angela Lamarca Richard A. Hubner Juan W. Valle Salma Alam Sumsur Chowdhury Yuk Ting Ma Livia Archibugi Gabriele Capurso Patrick Maisonneuve Albrecht Neesse Malin Sund Sebastian Krug 《Pancreatology》2019,19(1):97-104
Background
Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis. Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma (MPA). Randomized clinical trials evaluating intensified chemotherapies including FOLFIRINOX and nab-paclitaxel plus gemcitabine (NAB+GEM) have shown improvement in survival. Here, we have evaluated the efficacy of intensified chemotherapy versus gemcitabine monotherapy in real-life settings across Europe.Methods
A retrospective multi-center study including 1056 MPA patients, between 2012 and 2015, from nine centers in UK, Germany, Italy, Hungary and the Swedish registry was performed. Follow-up was at least 12 months. Cox proportional Harzards regression was used for uni- and multivariable evaluation of prognostic factors.Results
Of 1056 MPA patients, 1030 (98.7%) were assessable for survival analysis. Gemcitabine monotherapy was the most commonly used regimen (41.3%), compared to FOLFIRINOX (n = 204, 19.3%), NAB+GEM (n = 81, 7.7%) and other gemcitabine- or 5-FU-based regimens (n = 335, 31.7%). The median overall survival (OS) was: FOLFIRINOX 9.9 months (95%CI 8.4–12.6), NAB+GEM 7.9 months (95%CI 6.2–10.0), other combinations 8.5 months (95%CI 7.7–9.3) and gemcitabine monotherapy 4.9 months (95%CI 4.4–5.6). Compared to gemcitabine monotherapy, any combination of chemotherapeutics improved the survival with no significant difference between the intensified regimens. Multivariable analysis showed an association between treatment center, male gender, inoperability at diagnosis and performance status (ECOG 1–3) with poor prognosis.Conclusion
Gemcitabine monotherapy was predominantly used in 2012–2015. Intensified chemotherapy improved OS in comparison to gemcitabine monotherapy. In real-life settings, the OS rates of different treatment approaches are lower than shown in randomized phase III trials. 相似文献73.
Nicola M. Martucci Ilaria Rea Immacolata Ruggiero Monica Terracciano Luca De Stefano Nunzia Migliaccio Camillo Palmieri Giuseppe Scala Paolo Arcari Ivo Rendina Annalisa Lamberti 《Biomedical optics express》2015,6(4):1353-1362
In this paper, a new strategy for highly selective and sensitive direct detection of lymphoma cells by exploiting the interaction between a peptide and its B-cell receptor, has been evaluated. In particular, an idiotype peptide, able to specifically bind the B-cell receptor of A20 cells in mice engrafted with A20 lymphoma, has been used as molecular probe. The new detection technique has been demonstrated on a planar crystalline silicon chip. Coverage of 85% of silicon surface and detection efficiency of 8.5 × 10−3 cells/μm2 were obtained. The recognition strategy promises to extend its application in studying the interaction between ligands and their cell-surface receptors.OCIS codes: (000.1430) Biology and medicine, (280.1415) Biological sensing and sensors 相似文献
74.
75.
Matias Trillini Monica Cortinovis Piero Ruggenenti Jorge Reyes Loaeza Karen Courville Claudia Ferrer-Siles Silvia Prandini Flavio Gaspari Antonio Cannata Alessandro Villa Annalisa Perna Eliana Gotti Maria Rosa Caruso Davide Martinetti Giuseppe Remuzzi Norberto Perico 《Journal of the American Society of Nephrology : JASN》2015,26(5):1205-1214
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 µg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8–152.0) to 63.3 (52.0–79.7) pg/ml (P<0.001) but not on nonparicalcitol therapy. At 6 months, levels significantly differed between treatments (P<0.001 by analysis of covariance). Serum bone-specific alkaline phosphatase and osteocalcin decreased on paricalcitol therapy only and significantly differed between treatments at 6 months (P<0.001 for all comparisons). At 6 months, urinary deoxypyridinoline-to-creatinine ratio and 24-hour proteinuria level decreased only on paricalcitol (P<0.05). L3 and L4 vertebral mineral bone density, assessed by dual-energy x-ray absorption, significantly improved with paricalcitol at 6 months (P<0.05 for both densities). Paricalcitol was well tolerated. Overall, 6-month paricalcitol supplementation reduced parathyroid hormone levels and proteinuria, attenuated bone remodeling and mineral loss, and reduced eGFR in renal transplant recipients with secondary hyperparathyroidism. Long-term studies are needed to monitor directly measured GFR, ensure that the bone remodeling and mineral effects are sustained, and determine if the reduction in proteinuria improves renal and cardiovascular outcomes. 相似文献
76.
Dieli F Sireci G Caccamo N Di Sano C Titone L Romano A Di Carlo P Barera A Accardo-Palumbo A Krensky AM Salerno A 《The Journal of infectious diseases》2002,186(12):1835-1839
Vgamma9/Vdelta2 T cells can contribute to protective immune response against Mycobacterium tuberculosis, although the extent to which and mechanisms by which they could actually protect against human tuberculosis remain unclear. We have previously reported that Vgamma9/Vdelta2 T cells from tuberculin purified protein derivative (PPD)-positive children, either healthy or affected by different clinical forms of tuberculosis, strongly proliferate to different phosphoantigens in vitro, whereas Vgamma9/Vdelta2 T cells from PPD-negative healthy subjects proliferate very poorly. We report here that Vgamma9/Vdelta2 T cells from tuberculous children have an increased proliferative activity, but decreased interferon (IFN)-gamma production and granulysin expression. After successful chemotherapy, the Vgamma9/Vdelta2 T cell proliferative response strongly decreased, whereas IFN-gamma and granulysin production consistently increased. Disease-associated changes in Vgamma9/Vdelta2 T cell effector functions in patients with tuberculosis are consistent with the possibility that these T cells may play a protective role in immune response against M. tuberculosis infection. 相似文献
77.
Maria Luisa Torre Giuseppina T. Russo Marta Ragonese Annalisa Giandalia Ernesto De Menis Giorgio Arnaldi Angela Alibrandi Carmelo Buda Giovanni Romanello Elisabetta L. Romeo Domenico Cucinotta Francesco Trimarchi Salvatore Cannavo 《Pituitary》2014,17(3):257-266
Background
Acromegalic patients have a higher risk of developing colorectal tumours (CRT). The common C677T polymorphism in methylenetetrahydrofolate reductase (MTHFR) gene is a well-documented CRT risk factor in the general population, but its role in acromegaly has never been examined.Purpose
We investigated the influence of MTHFR C677T polymorphism, folate status and other lifestyle, nutritional and disease-specific variables on CRT risk in acromegaly.Methods
Clinical data were collected from 115 acromegalic patients (25 with active disease) who underwent a complete colonoscopy. C677T MTHFR genotype, homocysteine, vitamin B12, insulin growth factor and insulin levels, as well as metabolic variables were evaluated.Results
Colorectal tumours were identified in 51 patients (3 adenocarcinomas). MTHFR C677T distribution was in the Hardy–Weinberg equilibrium and similar in patients with or without CRT. There was a correlation between patients with TT genotype and CRT occurrence (Spearman’s test: P = 0.03), with an Odds Ratio (OR) of 1.32 (95 % CI 0.522–3.362, P NS). A folate–MTHFR genotype interaction on CRT risk was found (P = 0.037): in the lower folate subgroup, TT patients showed a 2.4 higher OR for CRT (95 % CI 0.484–11.891; P NS) than C-allele carriers. Smoking (P = 0.007), increased HbA1c levels (P = 0.021), dyslipidaemia (P = 0.049), acromegaly control (P = 0.057), and folate–MTHFR genotype interaction (P = 0.088) were associated with CRT at multivariate analysis.Conclusions
In this cohort of acromegalic patients, CRT risk is increased in 677TT MTHFR patients with low plasma folate levels. Smoking, high HbA1c levels, dyslipidaemia and disease activity were also associated with increased CRT risk. 相似文献78.
79.
80.
Annalisa Angelini Chiara Castellani Marny Fedrigo Onno J. de Boer Lorine B. Meijer-Jorna Xiaofei Li Marialuisa Valente Gaetano Thiene Allard C. van der Wal 《Virchows Archiv : an international journal of pathology》2014,464(6):627-635
Cardiac allograft vasculopathy is regarded as a progressive and diffuse intimal hyperplastic lesion of arteries and veins that leads to insidious vessel narrowing and to allograft ischemic disease, such as acute myocardial infarction or sudden cardiac death. The coronary lesions in transplanted hearts are considered as a particular type of arteriosclerosis with many similarities but also significant differences compared to native coronary atherosclerosis. It is particularly difficult for pathologists to systematically classify the lesions and to elucidate their origins, since over time, the allograft immune responses cause vascular pathology characterized by not only the onset of de novo fibrocellular lesions but also remodeling of already-existing native atherosclerotic lesions in the donor heart. Intraplaque hemorrhages, which result from newly formed leaky microvessels, may cause rapid increase of stenosis and generate a substrate for plaque destabilization. Comparing cardiac allograft vasculopathy from explanted hearts at autopsy with native coronary atherosclerosis from hearts removed at transplantation has revealed that ongoing intraplaque hemorrhages are also an important feature of cardiac allograft vasculopathy and may be important factors in the rapid progression of cardiac allograft vasculopathy. 相似文献